JINYU(SH:600201)2014-04-28 16:00Financial Performance - Net profit attributable to shareholders increased by 23.59% to CNY 137,847,155.55 compared to the same period last year[10] - Operating revenue rose by 112.04% to CNY 336,185,609.05 compared to the same period last year[10] - Basic earnings per share rose by 22.50% to CNY 0.49 compared to the same period last year[10] - Operating profit reached ¥163,592,390.66, representing a growth of 14.5% compared to ¥142,461,397.57 last year[22] - Net profit attributable to shareholders was ¥137,847,155.55, an increase of 23.6% from ¥111,537,672.33 in the same period last year[22] Cash Flow - Cash flow from operating activities turned positive with a net amount of CNY 131,868,042.52, compared to a negative cash flow of CNY -27,597,943.06 in the same period last year[10] - Cash received from operating activities increased by CNY 74.37 million, a growth of 401.11%, mainly due to the recovery of inter-company receivables from subsidiary transfers[16] - The net cash flow from operating activities was -27,494,020.22 RMB, an improvement from -109,156,154.51 RMB in the previous period, indicating a significant reduction in losses[28] - Total cash inflow from operating activities amounted to 96,427,956.15 RMB, compared to 7,053,501.03 RMB in the prior period, showing a substantial increase[28] - Cash outflow from operating activities totaled 123,921,976.37 RMB, up from 116,209,655.54 RMB, reflecting increased operational expenditures[28] Assets and Liabilities - Total assets increased by 5.44% to CNY 1,804,810,761.35 compared to the end of the previous year[10] - Total current assets amounted to CNY 1,248.18 million, up from CNY 1,161.66 million at the beginning of the year[17] - Total non-current assets reached CNY 556.63 million, slightly up from CNY 550.00 million at the beginning of the year[17] - Total liabilities decreased to CNY 385.17 million from CNY 429.83 million at the beginning of the year[18] - Total equity attributable to shareholders increased to CNY 1,419.64 million from CNY 1,281.79 million at the beginning of the year[18] Investments and Financing - Cash received from investments was CNY 58.06 million, mainly from the receipt of part of the restricted stock incentive funds[16] - Cash from borrowings decreased by CNY 308.95 million, with no new short-term or long-term borrowings during the period[16] - Cash inflow from financing activities was 58,055,400.00 RMB, a decrease from 100,001,246.27 RMB in the previous period, indicating reduced financing activities[28] - The net cash flow from financing activities was 58,029,990.41 RMB, down from 98,101,843.15 RMB, suggesting a decline in financing efficiency[28] Operational Efficiency - Cash paid for purchasing goods and services decreased by CNY 34.45 million, a reduction of 39.92%, primarily due to decreased project payments after the transfer of the real estate subsidiary[16] - Cash paid for fixed assets, intangible assets, and other long-term assets increased by CNY 12.74 million, an increase of 50.48%, mainly due to significant payments for engineering and equipment related to the upgrade of the biopharmaceutical industry[16] - Operating costs were ¥172,598,411.30, up 58.5% from ¥109,067,948.37 in the previous period[22] - The financial expenses showed a significant reduction, with a net income of -¥581,143.98 compared to a cost of ¥6,346,425.52 last year[22] Shareholder Information - The number of shareholders increased to 11,530 by the end of the reporting period[12] - The company received government subsidies amounting to CNY 120,000, which were closely related to its normal business operations[9] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[22]